Galera reports Q3 net loss $16M; avasopasem NDA on track by year-end

Galera Therapeutics, Inc.

2022-Q3 EPS reported -$1.72

Net loss of $16M ($0.60/share) vs $22.6M ($0.86) in Q3 2021; cash $42.8M.
NDA for avasopasem in radiotherapy-induced severe oral mucositis remains on track for submission by end of 2022.
One-year ROMAN follow-up showed tumor outcomes and overall survival maintained; 50% reduction in chronic kidney disease (10% vs 20% placebo, p=0.0043).
Meta-analysis of ROMAN and GT-201 (n=551) showed reductions in SOM incidence, duration, onset, and severity.
Appointed Eugene P. Kennedy, M.D., as Chief Medical Officer, succeeding Jon T. Holmlund who plans to retire.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Galera Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income ($16.0) million, or $(0.60) per share, EPS $(0.60) per share.

Period: the third quarter ended September 30, 2022
Net income: ($16.0) million, or $(0.60) per share
EPS: $(0.60) per share
Result: reported results

Exact text from the filing

Galera reported a net loss of ($16.0) million, or $(0.60) per share, for the third quarter of 2022, compared to a net loss of $(22.6) million, or $(0.86) per share, for the same period in 2021.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-280669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.